Compare Citius Pharmaceuticals Inc (CTXR) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs TotalEnergies SE — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while TotalEnergies SE trades at $86.61 (market cap $191.82B). The key difference: TotalEnergies SE is far larger — about 14083.7× Citius Pharmaceuticals Inc's market cap, and TotalEnergies SE pays a 4.93% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and TotalEnergies SE for 90 Days on average.
| CTXR | TTE | |
|---|---|---|
Market Cap | $13.62M | $191.82B |
Volume | 132,438 | 3,311,339 |
Sector | Health | Energy |
52-Week High | $1.82 | $93.60 |
52-Week Low | $0.48 | $57.39 |
Typical Hold Time | 16 Days | 90 Days |
Enterprise Value | $3.79M | $222.81B |
Dividend Yield | — | 4.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
TotalEnergies (TTE) trades at $84.23, up 0.3% on the day, with a bearish technical signal from moving averages but neutral oscillators. The stock shows attractive valuation with a P/E of 10.54 and P/S of 0.94. Recent earnings beat expectations in Q1 and Q2 2026, though revenue has declined from 2022 peaks. The company maintains a strong cash flow profile and has announced a $10 billion investment in Argentina, alongside a commitment to grow dividends by 5% annually through 2030.
The outlook is supported by strategic expansions in LNG and power, but risks include volatile energy prices and execution of capital projects. Analyst consensus is bullish with a $95.33 price target, implying potential upside. Investors should weigh the company's solid fundamentals and shareholder returns against sector-specific headwinds and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
